Drug Treatments and Lifestyle Based Interventions Share Spotlight At First Ever Alzheimer's Association Prevention Conference
Treatment of Alzheimer's Disease
A number of innovative treatment possibilities, including a new version of an anti-inflammatory drug, a low-intensity calisthenics program and what may be the next chapter in the Alzheimer vaccine story, all show some promise for Alzheimer's disease as demonstrated by new research studies reported today at the first Alzheimer's Association International Conference on Prevention of Dementia.
"We are very encouraged to see a diversity of approaches to treating Alzheimer's showing some level of success," said Steven DeKosky, M.D., director of the Alzheimer's Disease Research Center at the University of Pittsburgh and a member of the Alzheimer's Association Board of Directors. "The urgency of developing better treatments for Alzheimer's demands that we pursue every available avenue."
Several of the new treatment methods target beta amyloid, an abnormal brain protein thought to have an important role in Alzheimer's disease. The abnormal protein collects into sticky bundles in the brain called plaques. Investigators continue to study whether it is the beta amyloid itself, some further modified form of the abnormal protein, or the plaques that cause the death of brain cells in Alzheimer's.
"Amyloid as a possible cause for Alzheimer's is the most mature theory of the disease, and must be thoroughly tested," said William Thies, Ph.D., Alzheimer's Association vice president for Medical